Table 4 Characteristics of pediatric critically ill patients with MDR-Gram negative organism with Intravenous polymyxin B use

Age median (range)

7 month ( 1 month - 12 yrs)

Gender

  Males

7(50%)

Underlying disease

  CVS

8(57.1%)

  CNS

4(28.6%

  Respiratory

2(14.3%)

Site of infection

  Respiratory

11(78.6%)

  BSI

1(7.1%)

  BSI + Respiratory

2(14.3%)

Isolated organisms in Blood (n = 3)

  Acinetobacter Species

1

  Pseudomonas Aeruginosa

1

  Klebsiella Pneumoniae

1

Isolated organisms in respiratory secretions (n = 15)

  Acinetobacter Species

9

  Pseudomonas Aeruginosa

4

  Klebsiella Pneumoniae

1

  Enterobacter species

1

Antibiotics used prior to Polymyxin B

Ceftriaxone, Meropenem, Vancomycin

Antibiotics used concomitantly with Polymyxin B

Meropenem, Vancomycin, Tobramycin, Ciprofloxacin

PICU stay before instillation of IV Polymyxin B in days median (range)

7.0(1–17 days)

Duration of IV Polymyxin B treatment in days median (range)

8.5(2–14 days)

Dosage of Polymyxin B

40,000 IU/kg/day

Nephrotoxicity

3(21.4%)

Serum creatinine before Polymyxin B use (mg/dl) median (range)

0.41(0.1-1.2)

Serum creatinine after Polymyxin B use (mg/dl) median (range)

0.55(0.1-1.6)

Neurotoxicity

0

Outcome

  Expired

6(42.9%)

  Survived

8(57.1%)